Windlas Biotech Ltd (WINDLAS) is currently trading at 884.45 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Windlas Biotech is a vertically integrated Indian pharmaceutical manufacturer and CDMO operating multiple Dehradun-based plants across three strategic business verticals: CDMO services and products, domestic trade generics and OTC brands, and exports, focusing on complex generics, oral solids, liquids and injectables with an emphasis on technical formulation capabilities and customer audits. In Q1 FY27 Windlas reported its highest ever quarterly revenue of INR248 crores, an 18% year-on-year increase, extending a record streak of 14 consecutive quarters of growth; management also completed a INR47 crore buyback, reported EPS of INR8.46, and highlighted EBITDA expansion excluding non-cash ESOP charges, signalling improving operational leverage and shareholder returns. Plant 6 has achieved mechanical completion and is targeted to be commercialized in H1 FY27, with management estimating an initial OSD revenue capacity potential of around INR1,100 crores and incremental depreciation roughly INR3 crore per quarter; the company expects further upside via de-bottlenecking and internal efficiency initiatives to lift output above initial estimates. The CDMO vertical delivered standout momentum this quarter with reported 29% growth driven mainly by volume-led conversions and higher-value products; injectables are beginning to contribute after prior commissioning, exports are accelerating from a small base with regulatory registrations and audits in progress, while trade generics were impacted by codeine delistings and mix shifts.

Over the past 52 weeks, Windlas Biotech Ltd has traded between a low of ₹699.35 and a high of ₹1,181.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Windlas Biotech Ltd has a market capitalization of approximately 1,815.47. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Windlas Biotech Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 27.32 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,815.47 Cr, Windlas Biotech Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Windlas Biotech Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Windlas Biotech Ltd is 27.32. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Windlas Biotech’s conference call is scheduled for August 11, 2026, at 11:30 AM IST to discuss results for the quarter ended June 30, 2026.

Net sales were ₹238.50 crore for the quarter ending March 2026 (Q4 FY26), as reported in the provided quarterly results table.

Windlas Biotech reported FY26 revenue of ₹904 crore, up 19% year on year.